Atherosclerosis is the thickening and loss of elasticity of the walls of arteries that is associated with the formation of atherosclerotic plaques within the arterial intima. Inflammation has an ...

Artelo's Phase 1 study of ART26.12, a selective FABP5 inhibitor, progresses with safety data from the first cohort of healthy volunteers. ART27.13 showed promising results in stabilizing or ...

SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...

ART26.12 is the lead compound in Artelo's proprietary Fatty Acid Binding Protein (FABP) platform and is believed to be the first-ever selective FABP5 inhibitor to enter clinical trials.

Request permissions for this article. From the Saha Cardiovascular Research Center (C.W., A.D., H.S.L.), University of Kentucky, Lexington. Department of Physiology ...

Ley has received research funding for developing an atherosclerosis vaccine formulation from United Bioscience, Inc. The other author reports no conflicts. This work was supported by grants to D. Wolf ...

ART26.12 is the lead compound in Artelo’s proprietary FABP platform and is believed to be the first-ever selective FABP5 inhibitor to enter clinical trials. The FABP5 target is an intracellular ...